Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944258 | 0.85 | TDP1 (0.51) | TDP1L3MBTL1ITGB3ITGA2BCHEK2 | |
| Hydrochloric Acid SCHEMBL9196956 | 0.84 | TDP1 (0.50) | TDP1L3MBTL1ITGB3ITGA2BCHEK2 | |
| Succinic Acid SCHEMBL9213983 | 0.81 | ITGB3 (0.56) | TDP1L3MBTL1ITGB3ITGA2BCHEK2 | |
| SCHEMBL1169146 | 0.80 | GPR119 (0.52) | KMT2AMEN1POLBCHEK2 | |
| SCHEMBL9219032 | 0.80 | ITGB3 (0.54) | TDP1L3MBTL1ITGB3ITGA2B | |
| SCHEMBL4681513 | 0.79 | ALDH1A1 (0.49) | KMT2APOLBRAB9ASMN1; SMN2 | |
| SCHEMBL8155574 | 0.79 | L3MBTL1 (0.60) | TDP1L3MBTL1KMT2AMEN1POLB | |
| SCHEMBL13144594 | 0.79 | HTR2C (0.46) | L3MBTL1KMT2AMEN1DHODH | |
| SCHEMBL1168177 | 0.78 | MAPT (0.52) | TDP1L3MBTL1KMT2AMEN1POLB | |
| SCHEMBL931897 | 0.78 | KMT2A (0.69) | TDP1L3MBTL1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150526-B1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-8907096-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140315905-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC | 2014-10-23 | — | — | US | disclosed |
| US-8809540-B2 | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130231341-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8383820-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8334305-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110039853-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-02-17 | — | — | US | disclosed |
| US-20100331366-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS ,LLC (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2150526-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2010-02-10 | — | — | EP | disclosed |
| EP-2129652-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008101914-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (GB) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101907-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (GB) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039853-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | TDP1 2110/4885L3MBTL1 3824/4885KMT2A 3112/4885 |
| US-20130231341-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | TDP1 2110/4885L3MBTL1 3824/4885KMT2A 3112/4885 |
| US-20140315905-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | TDP1 2110/4885L3MBTL1 3824/4885KMT2A 3112/4885 |
| US-20100331366-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | TDP1 2000/4885L3MBTL1 3534/4885KMT2A 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.